MX2015006152A - Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m. - Google Patents
Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m.Info
- Publication number
- MX2015006152A MX2015006152A MX2015006152A MX2015006152A MX2015006152A MX 2015006152 A MX2015006152 A MX 2015006152A MX 2015006152 A MX2015006152 A MX 2015006152A MX 2015006152 A MX2015006152 A MX 2015006152A MX 2015006152 A MX2015006152 A MX 2015006152A
- Authority
- MX
- Mexico
- Prior art keywords
- inhibitors
- egfr mutants
- containing egfr
- aminopyrimidine compounds
- formula
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/538—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/08—Bridged systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Abstract
Esta invención se refiere a nuevos compuestos que son inhibidores de mutantes de EGFR que contienen T790M, a composiciones farmacéuticas que los contienen, a procesos para su preparación y a su uso en terapia para la prevención o el tratamiento de cáncer.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261728487P | 2012-11-20 | 2012-11-20 | |
US201361784494P | 2013-03-14 | 2013-03-14 | |
US201361866164P | 2013-08-15 | 2013-08-15 | |
PCT/US2013/070788 WO2014081718A1 (en) | 2012-11-20 | 2013-11-19 | Aminopyrimidine compounds as inhibitors of t790m containing egfr mutants |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2015006152A true MX2015006152A (es) | 2016-01-20 |
Family
ID=49681225
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2015006152A MX2015006152A (es) | 2012-11-20 | 2013-11-19 | Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m. |
Country Status (10)
Country | Link |
---|---|
US (1) | US9890152B2 (es) |
EP (2) | EP3181564B1 (es) |
JP (1) | JP6430390B2 (es) |
KR (1) | KR20150087850A (es) |
CN (1) | CN104955824B (es) |
BR (1) | BR112015011456A2 (es) |
CA (1) | CA2891655A1 (es) |
MX (1) | MX2015006152A (es) |
RU (1) | RU2015118647A (es) |
WO (1) | WO2014081718A1 (es) |
Families Citing this family (47)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2010286168B2 (en) | 2009-08-20 | 2014-05-15 | Karus Therapeutics Limited | Tricyclic heterocyclic compounds as phosphoinositide 3-kinase inhibitors |
GB201204125D0 (en) | 2012-03-08 | 2012-04-25 | Karus Therapeutics Ltd | Compounds |
EP2818472A1 (en) * | 2013-06-27 | 2014-12-31 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Imidazo[4,5-c]pyridine and pyrrolo[3,2-c]pyridine compounds as G-protein-coupled receptor kinase 5 (GRK5) modulators |
WO2014210354A1 (en) | 2013-06-28 | 2014-12-31 | Genentech, Inc. | Azaindazole compounds as inhibitors of t790m containing egfr mutants |
US10125144B2 (en) * | 2013-10-07 | 2018-11-13 | Kadmon Corporation, Llc | Rho kinase inhibitors |
JO3805B1 (ar) | 2013-10-10 | 2021-01-31 | Araxes Pharma Llc | مثبطات كراس جي12سي |
US10016439B2 (en) * | 2014-01-31 | 2018-07-10 | Ono Pharmaceutical Co., Ltd. | Fused imidazole compounds |
GB201402431D0 (en) | 2014-02-12 | 2014-03-26 | Karus Therapeutics Ltd | Compounds |
EP3122730B1 (en) | 2014-03-28 | 2020-03-25 | Calitor Sciences, LLC | Substituted heteroaryl compounds and methods of use |
CN111170998B (zh) | 2014-11-05 | 2023-04-11 | 益方生物科技(上海)股份有限公司 | 嘧啶或吡啶类化合物、其制备方法和医药用途 |
CN108135906A (zh) * | 2015-07-24 | 2018-06-08 | 路易斯维尔大学研究基金会有限公司 | 治病化合物、组合物、方法、及化合物制备方法 |
GB201514754D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
GB201514751D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds |
GB201514758D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Formulation |
GB201514760D0 (en) | 2015-08-19 | 2015-09-30 | Karus Therapeutics Ltd | Compounds and method of use |
EP3347097B1 (en) | 2015-09-11 | 2021-02-24 | Sunshine Lake Pharma Co., Ltd. | Substituted aminopyrimidine derivatives as modulators of the kinases jak, flt3 and aurora |
WO2017114351A1 (en) * | 2015-12-27 | 2017-07-06 | Chongqing Fochon Pharmaceutical Co., Ltd. | Certain protein kinase inhibitors |
CN107266451B (zh) * | 2016-04-07 | 2021-12-31 | 上海医药工业研究院 | 瑞布昔利布中间体的制备方法 |
EP3559002A4 (en) | 2016-12-23 | 2021-02-17 | Arvinas Operations, Inc. | CHEMERICAL MOLECULES TARGETING EGFR PROTEOLYSIS AND RELATED METHODS OF USE |
RU2019125177A (ru) * | 2017-01-11 | 2021-02-15 | Лео Фарма А/С | Новые производные амино-имидазопиридина в качестве ингибиторов янус-киназы и их фармацевтическое применение |
EP3573964A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Benzothiophene and benzothiazole compounds and methods of use thereof |
EP3573954A1 (en) | 2017-01-26 | 2019-12-04 | Araxes Pharma LLC | Fused bicyclic benzoheteroaromatic compounds and methods of use thereof |
US11279689B2 (en) | 2017-01-26 | 2022-03-22 | Araxes Pharma Llc | 1-(3-(6-(3-hydroxynaphthalen-1-yl)benzofuran-2-yl)azetidin-1 yl)prop-2-en-1-one derivatives and similar compounds as KRAS G12C modulators for treating cancer |
CN110382482A (zh) | 2017-01-26 | 2019-10-25 | 亚瑞克西斯制药公司 | 稠合的杂-杂二环化合物及其使用方法 |
WO2018140514A1 (en) | 2017-01-26 | 2018-08-02 | Araxes Pharma Llc | 1-(6-(3-hydroxynaphthalen-1-yl)quinazolin-2-yl)azetidin-1-yl)prop-2-en-1-one derivatives and similar compounds as kras g12c inhibitors for the treatment of cancer |
JOP20180011A1 (ar) | 2017-02-16 | 2019-01-30 | Gilead Sciences Inc | مشتقات بيرولو [1، 2-b]بيريدازين |
GB201705263D0 (en) * | 2017-03-31 | 2017-05-17 | Probiodrug Ag | Novel inhibitors |
US11639346B2 (en) | 2017-05-25 | 2023-05-02 | Araxes Pharma Llc | Quinazoline derivatives as modulators of mutant KRAS, HRAS or NRAS |
BR112019024674A2 (pt) | 2017-05-25 | 2020-06-16 | Araxes Pharma Llc | Inibidores covalentes da kras |
AU2018294054B2 (en) * | 2017-06-30 | 2022-05-26 | Beijing Tide Pharmaceutical Co., Ltd. | Rho-associated protein kinase inhibitor, pharmaceutical composition comprising same, and preparation method and use thereof |
EP3728251A1 (en) * | 2017-12-18 | 2020-10-28 | F. Hoffmann-La Roche AG | Bifunctional inhibitors with egfr having a e3 ubiquitin ligase moiety |
TW201945357A (zh) | 2018-02-05 | 2019-12-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
CN111741954B (zh) | 2018-02-21 | 2024-04-02 | 勃林格殷格翰国际有限公司 | 用作egfr抑制剂的新型苯并咪唑化合物及衍生物 |
TWI721483B (zh) | 2018-07-13 | 2021-03-11 | 美商基利科學股份有限公司 | 吡咯并[1,2-b]嗒𠯤衍生物 |
CN112584833A (zh) * | 2018-08-01 | 2021-03-30 | 亚瑞克西斯制药公司 | 杂环螺化合物及其用于治疗癌症的使用方法 |
WO2020260252A1 (en) | 2019-06-24 | 2020-12-30 | Boehringer Ingelheim International Gmbh | New macrocyclic compounds and derivatives as egfr inhibitors |
CN114630820B (zh) * | 2019-10-30 | 2023-10-31 | 杨森科学爱尔兰无限公司 | 3-硝基-n-(2,2,2-三氟乙基)-4-吡啶胺的合成 |
CN113004252B (zh) * | 2019-12-20 | 2023-06-09 | 江苏先声药业有限公司 | 一种芳基并咪唑类衍生物及其用途 |
PE20221264A1 (es) | 2019-12-23 | 2022-08-16 | Blueprint Medicines Corp | Inhibidores de egfr |
CN116507627A (zh) | 2020-11-02 | 2023-07-28 | 勃林格殷格翰国际有限公司 | 作为egfr抑制剂的经取代1h-吡唑并[4,3-c]吡啶及衍生物 |
EP4301360A1 (en) * | 2021-03-02 | 2024-01-10 | Dana Farber Cancer Institute, Inc. | Covalent egfr inhibitors and methods of use thereof |
WO2022271612A1 (en) | 2021-06-22 | 2022-12-29 | Blueprint Medicines Corporation | Heterocyclic egfr inhibitors for use in the treatment of cancer |
WO2023283130A1 (en) | 2021-07-04 | 2023-01-12 | Newave Pharmaceutical Inc. | Isoquinoline derivatives as mutant egfr modulators and uses thereof |
CN116478136A (zh) * | 2022-01-17 | 2023-07-25 | 苏州浦合医药科技有限公司 | 2-哌啶基或2-吡唑基取代的嘧啶化合物作为egfr抑制剂 |
WO2023146786A1 (en) * | 2022-01-28 | 2023-08-03 | Bridgene Biosciences, Inc. | Imidazopyridine inhibitors of tyrosine kinase |
WO2023211238A1 (ko) * | 2022-04-29 | 2023-11-02 | 보로노이 주식회사 | 헤테로아릴 유도체 화합물 및 이의 용도 |
WO2023241618A1 (zh) * | 2022-06-14 | 2023-12-21 | 南京明德新药研发有限公司 | 氨基嘧啶类化合物及其应用 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5559235A (en) | 1991-10-29 | 1996-09-24 | Glaxo Wellcome Inc. | Water soluble camptothecin derivatives |
US5342947A (en) | 1992-10-09 | 1994-08-30 | Glaxo Inc. | Preparation of water soluble camptothecin derivatives |
US5681835A (en) | 1994-04-25 | 1997-10-28 | Glaxo Wellcome Inc. | Non-steroidal ligands for the estrogen receptor |
US5491237A (en) | 1994-05-03 | 1996-02-13 | Glaxo Wellcome Inc. | Intermediates in pharmaceutical camptothecin preparation |
GB9716557D0 (en) | 1997-08-06 | 1997-10-08 | Glaxo Group Ltd | Benzylidene-1,3-dihydro-indol-2-one derivatives having anti-cancer activity |
AU2001292670A1 (en) * | 2000-09-15 | 2002-03-26 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
JP4764823B2 (ja) * | 2003-10-06 | 2011-09-07 | グラクソ グループ リミテッド | キナーゼ阻害剤としての1,6−二置換アザベンゾイミダゾールの調製 |
US20070185106A1 (en) | 2004-02-20 | 2007-08-09 | Astrazeneca Ab | Pyrrole derivatives as gonadotropin releasing hormone (gnrh) antagonists |
BRPI0710182A2 (pt) | 2006-03-31 | 2012-08-07 | Novartis Ag | compostos orgÂnicos. |
MX2010004499A (es) | 2007-10-24 | 2010-05-20 | Astellas Pharma Inc | Compuesto de azolcarboxamida o sal de el. |
WO2011036576A1 (en) | 2009-09-23 | 2011-03-31 | Pfizer Inc. | Gpr 119 modulators |
US20110207736A1 (en) * | 2009-12-23 | 2011-08-25 | Gatekeeper Pharmaceuticals, Inc. | Compounds that modulate egfr activity and methods for treating or preventing conditions therewith |
WO2011106276A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Task channel antagonists |
JP5766820B2 (ja) | 2011-02-09 | 2015-08-19 | エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft | Pi3キナーゼ阻害剤としての複素環化合物 |
-
2013
- 2013-11-19 MX MX2015006152A patent/MX2015006152A/es unknown
- 2013-11-19 JP JP2015543116A patent/JP6430390B2/ja not_active Expired - Fee Related
- 2013-11-19 WO PCT/US2013/070788 patent/WO2014081718A1/en active Application Filing
- 2013-11-19 RU RU2015118647A patent/RU2015118647A/ru not_active Application Discontinuation
- 2013-11-19 CA CA2891655A patent/CA2891655A1/en not_active Abandoned
- 2013-11-19 EP EP17152475.4A patent/EP3181564B1/en active Active
- 2013-11-19 CN CN201380070943.5A patent/CN104955824B/zh not_active Expired - Fee Related
- 2013-11-19 BR BR112015011456A patent/BR112015011456A2/pt not_active IP Right Cessation
- 2013-11-19 EP EP13798885.3A patent/EP2922851B8/en active Active
- 2013-11-19 KR KR1020157016164A patent/KR20150087850A/ko not_active Application Discontinuation
-
2015
- 2015-06-19 US US14/745,159 patent/US9890152B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US9890152B2 (en) | 2018-02-13 |
EP3181564A1 (en) | 2017-06-21 |
KR20150087850A (ko) | 2015-07-30 |
EP2922851A1 (en) | 2015-09-30 |
RU2015118647A (ru) | 2017-01-10 |
EP3181564B1 (en) | 2019-09-18 |
CA2891655A1 (en) | 2014-05-30 |
CN104955824A (zh) | 2015-09-30 |
JP6430390B2 (ja) | 2018-11-28 |
JP2016500075A (ja) | 2016-01-07 |
EP2922851B8 (en) | 2017-09-27 |
EP2922851B1 (en) | 2017-07-26 |
CN104955824B (zh) | 2017-09-22 |
BR112015011456A2 (pt) | 2017-07-11 |
WO2014081718A1 (en) | 2014-05-30 |
US20160016948A1 (en) | 2016-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2015006152A (es) | Compuestos de aminopirimidina como inhibidores de mutantes de egfr que contienen t7 9 0m. | |
PH12017502141A1 (en) | Compounds and their methods of use | |
PH12015502414A1 (en) | Enhancer of zeste homolog 2 inhibitors | |
PH12016501898A1 (en) | Quinoxaline derivatives useful as fgfr kinase modulators | |
PH12015501385A1 (en) | Autotaxin inhibitors | |
NZ700928A (en) | Dna-pk inhibitors | |
MX2020010535A (es) | Inhibidor de ezh2 para usarse en el tratamiento de sarcoma epiteloide. | |
PH12014502772A1 (en) | Substituted tricyclic compounds as fgfr inhibitors | |
PH12013502565A1 (en) | Substituted imidazopyridinyl-aminopyridine compounds | |
WO2013173441A3 (en) | Enhancer of zeste homolog 2 inhibitors | |
EA024842B9 (ru) | Соединения в качестве модуляторов протеинкиназы pi3k | |
MX353806B (es) | Quinolinas como moduladores de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr). | |
UA111386C2 (uk) | Піридопіразини, які мають протиракову активність через інгібування fgfr-кіназ | |
EA023222B8 (ru) | Пиразолилхиноксалиновые ингибиторы киназы | |
MX2014004861A (es) | Benzopirazinas anticancerigenas via la inhibicion de cinasas del receptor del factor de crecimiento de fibroblasto (fgfr). | |
MX2013010898A (es) | Novedoso derivados de la pirimidina. | |
MX2014000964A (es) | Derivados aza heterociclicos sustituidos. | |
MX354024B (es) | Uso de array-380 y ar00440993 para el tratamiento de cancer de cerebro. | |
UA110793C2 (uk) | Піразолілхіноксалінові інгібітори кінази |